NCT00913549View on ClinicalTrials.gov

To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 1989

Primary Completion Date

January 31, 1990

Study Completion Date

January 31, 1990

Conditions
Allergy
Interventions
DRUG

Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)

DRUG

Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY